In contrast, attenuated LC3A/B-II formation through inhibiting ULK1/2 or VPS34 complexes was also reflected in the differential killing efficacy of P3 and T98G GBM cells, as was treatment with BTZ alone. The gene discussed is MAP1LC3A; the disease is glioblastoma.